Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Capital Expenditures (2021 - 2025)

Rxo (RXO) has disclosed Capital Expenditures for 5 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 33.33% year-over-year to $16.0 million, compared with a TTM value of $59.0 million through Dec 2025, up 31.11%, and an annual FY2025 reading of $59.0 million, up 31.11% over the prior year.
  • Capital Expenditures was $16.0 million for Q4 2025 at Rxo, up from $14.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $18.0 million in Q4 2022 and bottomed at $9.0 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $13.8 million, with a median of $14.0 million recorded in 2025.
  • The sharpest move saw Capital Expenditures soared 100.0% in 2022, then plummeted 38.89% in 2024.
  • Year by year, Capital Expenditures stood at $9.0 million in 2021, then skyrocketed by 100.0% to $18.0 million in 2022, then changed by 0.0% to $18.0 million in 2023, then tumbled by 33.33% to $12.0 million in 2024, then soared by 33.33% to $16.0 million in 2025.
  • Business Quant data shows Capital Expenditures for RXO at $16.0 million in Q4 2025, $14.0 million in Q3 2025, and $14.0 million in Q2 2025.